chicago_biz
3 records
courtlistener_docket
5 records
Ousler, III v. ELI LILLY & COMPANY
2026-06-03
Federal docket 2:26-cv-03821 (paed); matched party 'ELI LILLY & COMPANY'
View Source
Hafeli v. ELI LILLY & COMPANY
2026-05-13
Federal docket 2:26-cv-03254 (paed); matched party 'ELI LILLY & COMPANY'
View Source
Moffett, III v. ELI LILLY & COMPANY
2026-05-01
Federal docket 2:26-cv-02885 (paed); matched party 'ELI LILLY & COMPANY'
View Source
Henderson v. ELI LILLY & COMPANY
2026-04-15
Federal docket 2:26-cv-02463 (paed); matched party 'ELI LILLY & COMPANY'
View Source
Cormier v. ELI LILLY & COMPANY
2026-04-01
Federal docket 2:26-cv-02124 (paed); matched party 'ELI LILLY & COMPANY'
View Source
epa_echo
1 records
fda
5 records
FDA Drug Recall: Sterile Diluent, HUMALOG U-100 (insulin lispro injection), HUMULIN R U-100 REGUL
2024-04-24
Class II — CGMP Deviations
View Source
FDA Drug Recall: Glucagon Emergency Kit for Low Blood Sugar, Glucagon for Injection, 1 mg per via
2021-10-20
Class I — SUBPOTENT DRUG: Vial contained a liquid substance, instead of the expected powder substance. There was also a lack of full drug effect upon administration.
View Source
FDA Drug Recall: Trulicity (dulaglutide), 0.75 mg/0.5 mL, 4 Single-Dose Pens per box, Rx only, El
2021-09-01
Class II — Labeling: Label error on declared strength - autoinjector devices labeled as 0.75 mg / 0.5 mL actually contain 1.5 mg / 0.5 mL of product.
View Source
FDA Drug Recall: Zyprexa Intramuscular, Olanzapine for Injection, 10 MG per Single Use Vial, Rx o
2021-08-18
Class II — cGMP deviations: Atypical appearance, decrease in size and change in color of the lyophilized cake of drug product.
View Source
FDA Drug Recall: ERBITUX CETUXIMAB Injection, 200 mg/100 mL (2 mg/mL), 100 mL per single-use vial
2018-11-21
Class III — Labeling: Missing label; potential for missing primary container label on the vial.
View Source
ftc_enforcement
1 records
Eli Lilly & Co. and Sepracor, Inc.
2003-06-27
FTC live enforcement action FY2003; matched respondent 'Eli Lilly & Co.'
View Source
lobbying
4 records
Lobbying Client: ELI LILLY & COMPANY
Lobbied by THE HARPLE GROUP, LLC — Biopharmaceutical company
View Source
Lobbying Client: ELI LILLY & COMPANY
Lobbied by DLA PIPER LLP (US) — Biopharmaceutical company
View Source
Lobbying Client: ELI LILLY & COMPANY
Lobbied by THE HARPLE GROUP, LLC — Biopharmaceutical company
View Source
Lobbying Client: ELI LILLY & COMPANY
Lobbied by DLA PIPER LLP (US) — Biopharmaceutical company
View Source
OSHA
1 records
OSHA Inspection (Planned) - Eli Lilly & Co
1983-04-28
OSHA inspection at Eli Lilly & Co, Roanoke, VA. NAICS: 000000. SIC: 3089
View Source
SEC EDGAR
1 records
Be informed when major changes happen on C.F.A.I. — new data sources, platform updates, critical enforcement alerts
No spam. Only major updates. Unsubscribe anytime.